← back to search

Erlend B. Smeland

University of Oslo · NO
Area of research
Pathology and Forensic Medicine · Immunology
Research interest
Research focused on Lymphoma and Follicular lymphoma, with related work in Cancer research, Germinal center, Diffuse large B-cell lymphoma. Notable publications include 'Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics', 'Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue', and 'EZH2 mutations are frequent and represent an early event in follicular lymphoma'.
h-index
citations
2,342
works
7
NIH funding
primary concept
email

Recent publications

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances 2023cited by 27position: middledoi
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunology Research 2019cited by 114position: middledoi
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
British Journal of Haematology 2016cited by 69position: lastdoi
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
Blood 2014cited by 612position: middledoi
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
Nature 2014cited by 288position: middledoi
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Blood 2013cited by 321position: middledoi
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Nature 2012cited by 911position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jan Delabie · University Health Network3 papers (2014–2016)June H. Myklebust · Oslo University Hospital2 papers (2016–2019)Lisa M. Rimsza · Mayo Clinic2 papers (2014–2014)Wing C. Chan · Ontario Institute for Cancer Research2 papers (2014–2014)Dennis D. Weisenburger · University of Nebraska Medical Center2 papers (2014–2014)Louis M. Staudt · National Institutes of Health2 papers (2014–2014)Andreas Rosenwald · University of Bonn2 papers (2014–2014)Elı́as Campo · Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer2 papers (2014–2014)Randy D. Gascoyne · BC Cancer Agency2 papers (2014–2014)Yngvild Nuvin Blaker · University of Oslo2 papers (2016–2019)James R. Cook · Cleveland Clinic2 papers (2014–2014)Bjørn Østenstad · University of Oslo2 papers (2016–2019)German Ott · Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology2 papers (2014–2014)Klaus Beiske · University of Oslo2 papers (2016–2019)Rita M. Braziel · Oregon Health & Science University2 papers (2014–2014)Harald Holte · Oslo Cancer Cluster2 papers (2016–2019)Elaine S. Jaffe · National Institutes of Health2 papers (2014–2014)Raymond R. Tubbs · Case Western Reserve University2 papers (2014–2014)Kai Fu · Yunnan University1 papers (2014–2014)Ole Christian Lingjærde · University of Oslo1 papers (2016–2016)